We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer Inks Deal With Mammoth Bio to Develop Gene-Editing Therapies
Bayer Inks Deal With Mammoth Bio to Develop Gene-Editing Therapies
Bayer and Mammoth Biosciences have announced a deal in which Bayer will shell out $40 million now and potentially up to $1 billion over time for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.